계명대학교 의학도서관 Repository

항암제로서의 TNF-Related Apoptosis-Inducing Ligands (TRAIL)

Metadata Downloads
Author(s)
이태진권택규
Keimyung Author(s)
Kwon, Taeg Kyu
Department
Dept. of Immunology (면역학)
Journal Title
Journal of Cancer Prevention
Issued Date
2006
Volume
11
Issue
1
Abstract
TRAIL have been widely viewed as potential cancer therapeutics because of its specific apoptosisinducing capacity in tumor cells. The increased understanding of apoptosis pathways has directed attention to components of death receptor mediated apoptotic pathway as potential targets not only for chemotherapeutic but also for chemopreventive agents. An increasing number of previously identified chemotherapeutic and chemopreventive agents were found to increase the sensitivity to TRAIL-mediated apoptosis in a variety of premalignant and malignant cell types in vitro and in a few animal models in vivo. Also, phase 1 and 2 clinical trials using agonistic mAb that engage the human TRAIL receptor DR4 and DR5 have also provided encouraging results in cancer patients. Thus, understanding the control of death receptor-mediated apoptosis by chemotherapeutic and chemopreventive agents and their implications in cancer treatments may provide a rational approach for using such agents alone or in combination with TRAIL to enhance TRAIL-mediated apoptosis. In this study, we summarize biological agent and drug that sensitize tumors to TRAIL-mediated apoptosis and discuss the potential molecular basis for their sensitization.
Alternative Title
TNF-Related Apoptosis-Inducing Ligands (TRAIL) as a Therapeutic Agents in Cancer
Keimyung Author(s)(Kor)
권택규
Publisher
School of Medicine
Citation
이태진 and 권택규. (2006). 항암제로서의 TNF-Related Apoptosis-Inducing Ligands (TRAIL). Journal of Cancer Prevention, 11(1), 9–21.
Type
Article
ISSN
2288-3649
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/38076
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Immunology (면역학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.